<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04520152</url>
  </required_header>
  <id_info>
    <org_study_id>EFFORT</org_study_id>
    <nct_id>NCT04520152</nct_id>
  </id_info>
  <brief_title>Evaluation of the Free Flow Medical Lung Tensioning Device System for the Treatment of Severe Emphysema</brief_title>
  <acronym>EFFORT</acronym>
  <official_title>Evaluation of the Free Flow Medical Lung Tensioning Device System for the Treatment of Severe Emphysema - EFFORT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with severe emphysema have limited options for treatment. Current treatments include&#xD;
      lung transplant, lung volume reduction surgery or endobronchial lung volume reduction using&#xD;
      valves or coils. These options are only available for a small and selected group of patients.&#xD;
      The Free Flow Medical Lung Tensioning Device System (LTD) is thought to be the next&#xD;
      generation endobronchial treatment for patients with severe emphysema designed to address&#xD;
      this unmet need. The LTD is designed to compress the areas of lung parenchyma most damaged by&#xD;
      emphysema and to tension surrounding tissue to help restore lung elastic recoil in a similar&#xD;
      manner to the lung volume reduction coils.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2021</start_date>
  <completion_date type="Anticipated">December 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: type and frequency of device-related and procedure-related AE</measure>
    <time_frame>3 months</time_frame>
    <description>To evaluate the safety of the LTD in COPD patients with heterogeneous and homogeneous emphysema by evaluating the type and frequency of device-related and procedure-related AE experienced during and following LTD placement through the 3-month visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural succes</measure>
    <time_frame>3 months</time_frame>
    <description>To evaluate the feasibility of the LTD in COPD patients with heterogeneous and homogeneous emphysema by measuring the frequencies of successful and unsuccessful intended LTD placements.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance - Quality of Life: St George's Respiratory Questionnaire</measure>
    <time_frame>3 months</time_frame>
    <description>Change in St George's Respiratory Questionnaire total score</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Emphysema or COPD</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bronchoscopic LTD placement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FreeFlowMedical Lung Tensioning Device</intervention_name>
    <description>Bronchoscopic lung tensioning device implantation</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of COPD&#xD;
&#xD;
          2. FEV1/FVC ≤ 70%&#xD;
&#xD;
          3. ≥ 40 years of age&#xD;
&#xD;
          4. Post-bronchodilator FEV1 ≤ 45% of predicted&#xD;
&#xD;
          5. Total Lung Capacity &gt; 100% of predicted&#xD;
&#xD;
          6. Residual Volume (RV) &gt; 175% of predicted&#xD;
&#xD;
          7. RV/TLC &gt; 55%&#xD;
&#xD;
          8. Marked dyspnea defined by a score of ≥ 2 on mMRC dyspnea scale of 0-4&#xD;
&#xD;
          9. Emphysema with ≥ 20% destruction (on -950 Hounsfield units) of two potential treatment&#xD;
             lobe(s)&#xD;
&#xD;
         10. Stopped smoking for ≥ 6 months prior to entering the study&#xD;
&#xD;
         11. Completed a pulmonary rehabilitation program prior to entering the study and/or have&#xD;
             regular (at least once a week) physiotherapy&#xD;
&#xD;
         12. Ability to read, understand and sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of recurrent clinically significant respiratory infections and/or COPD&#xD;
             exacerbations, defined as ≥ 2 hospitalizations for respiratory infections and/or COPD&#xD;
             exacerbations during the year prior to enrolment&#xD;
&#xD;
          2. History of recurrent clinically significant respiratory infections and/or COPD&#xD;
             exacerbations, defined as ≥ 3 courses of prednisolone and/or antibiotics for&#xD;
             respiratory infections and/or COPD exacerbations during the year prior to enrolment&#xD;
&#xD;
          3. Clinically significant bronchiectasis&#xD;
&#xD;
          4. Severe gas exchange abnormalities defined by PaCO2 &gt; 7.0 kPa (52 mmHg) and/or PaO2 &lt;&#xD;
             7.0 kPa (52 mmHg) (measured on room air)&#xD;
&#xD;
          5. ≥ 10 mg prednisone (or equivalent dose of other corticosteroids) daily&#xD;
&#xD;
          6. Inability to walk &gt; 140 meters in 6 minutes&#xD;
&#xD;
          7. Known pulmonary hypertension defined by right ventricular systolic pressure &gt; 45 mmHg&#xD;
             and/or evidence of pulmonary hypertension of right ventricular failure on&#xD;
             echocardiogram&#xD;
&#xD;
          8. Significant paraseptal emphysema&#xD;
&#xD;
          9. Giant bullae (&gt;1/3 of lung volume)&#xD;
&#xD;
         10. Medical history of asthma&#xD;
&#xD;
         11. Underwent previous LVRS, lobectomy, pneumonectomy or lung transplant&#xD;
&#xD;
         12. Underwent previous treatment with thermal vapor ablation, AeriSeal, Cryospray,&#xD;
             endobronchial coils or endobronchial valves (if still implanted)&#xD;
&#xD;
         13. Evidence of other disease(s) that have a predicted survival of less than one year&#xD;
&#xD;
         14. Inability to tolerate bronchoscopy under general anaesthesia&#xD;
&#xD;
         15. Maintenance antiplatelet (except aspirin/Ascal) or anticoagulant therapy (such as&#xD;
             warfarin, Coumadin, heparin, LMWH, DOACs, etc) which cannot be permanently stopped&#xD;
             prior to entering the study&#xD;
&#xD;
         16. Pregnant, lactating or plans to become pregnant within the study timeframe&#xD;
&#xD;
         17. Known sensitivity to drugs required to perform bronchoscopy under general anaesthesia&#xD;
&#xD;
         18. Any other disease, condition(s) or habit(s) that would interfere with completion of&#xD;
             study and follow up assessments, would increase risks of bronchoscopy or assessments&#xD;
             or in the judgment of the investigator would potentially interfere&#xD;
&#xD;
         19. Known Nickel, Titanium, or Nitinol allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sharyn Roodenburg, MD, MSc</last_name>
    <phone>+31503616161</phone>
    <email>s.a.roodenburg@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karin Klooster, PhD</last_name>
    <phone>+31503616161</phone>
    <email>k.klooster@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept. of Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>D-69126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ralph Eberhardt, MD PhD</last_name>
      <email>Ralf.eberhardt@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Ralph Eberhardt, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felix Herth, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharyn Roodenburg, MD, MSc</last_name>
      <phone>+31503616161</phone>
      <email>s.a.roodenburg@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Dirk-Jan Slebos, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Koster, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Dirk-Jan Slebos</investigator_full_name>
    <investigator_title>Prof. dr. D.J. Slebos MD, PhD</investigator_title>
  </responsible_party>
  <keyword>lung volume reduction</keyword>
  <keyword>nitinol</keyword>
  <keyword>device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

